Amarantus BioScience Holdings, Inc.
AMBS
Rank in Stocks
#34021
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$63.04K
Change (1 day)
0.00%
Change (1 year)
-66.67%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Amarantus BioScience Holdings, Inc. (AMBS)
Category
Healthcare
EPS for Amarantus BioScience Holdings, Inc. (AMBS)
EPS as of March 2023 TTM: $0.00
According to Amarantus BioScience Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2022 the company had an EPS of $-0.01, an increase over its 2021 EPS of $-0.02.
EPS history for Amarantus BioScience Holdings, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -70.00% |
| 2022 | $-0.01 | -62.56% |
| 2021 | $-0.02 | 1,188.24% |
| 2020 | 0.00 | -102.50% |
| 2019 | $0.07 | -250.66% |
| 2018 | $-0.05 | -30.46% |
| 2017 | $-0.07 | -56.67% |
| 2016 | $-0.15 | -96.40% |
| 2015 | $-4.17 | -26.97% |
| 2014 | $-5.71 | 13.52% |
| 2013 | $-5.03 | -8.04% |
| 2012 | $-5.47 | -56.72% |
| 2011 | $-12.64 | 38,912.35% |
| 2010 | $-0.03 | 248.39% |
| 2009 | $-0.01 | -13.08% |
| 2008 | $-0.01 | 160.98% |
| 2007 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -522,100.00% |
US
|
|
| $-7.07 | 235,566.67% |
US
|
|
| $-5.29 | 176,233.33% |
AU
|
|
| $12.88 | -429,436.67% |
BE
|
|
| $21.56 | -718,766.67% |
NL
|
Questions about Amarantus BioScience Holdings, Inc.'s earnings per share (EPS)
What is Amarantus BioScience Holdings, Inc.'s earnings per share (EPS)?
Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $0.00, as of Mar 2023.
What was Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) in 2022?
In 2022, Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) was $-0.01, compared with $-0.02 in 2021.
How has Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) changed since 2017?
From 2017 to 2022, Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) was highest in 2019 ($0.07) and lowest in 2017 ($-0.07).
How does Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Amarantus BioScience Holdings, Inc.'s earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.